Activated Clotting Time and Haemostatic Complications in Patients Receiving ECMO Support: A Systematic Review
Journal of Cardiovascular Development and Disease · 13.07.2025 · 12 (7) · 267
DOI: 10.3390/jcdd12070267 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cardiovascular Development and Disease, online erschienen am 13.07.2025. Verfasst von Daniel Schwaiger und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anaesthesiology and Intensive Care, Medical University of Innsbruck, Anichstraße. 35, 6020 Innsbruck, Austria. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Extracorporeal membrane oxygenation (ECMO) requires systemic anticoagulation to prevent clotting, typically using unfractionated heparin (UFH). However, anticoagulation carries a bleeding risk, necessitating monitoring. Activated clotting time (ACT) is a commonly used monitoring tool for UFH anticoagulation. However, systematized evidence linking ACT monitoring with haemostatic complications (bleeding and thrombosis) is missing.
Methods
A systematic review (Scopus and PubMed, up to 13 July 2024) including studies reporting on the patients receiving ECMO support with UFH anticoagulation monitored using ACT was performed.
Results
A total of 3536 publications were identified, of which 30 (2379 patients) were included in the final review. Thirteen studies found no significant association between ACT values and haemorrhage, while four studies suggested a relationship between elevated ACT levels and bleeding events. Eight studies demonstrated no association between ACT values and the occurrence of thrombosis. Major bleeding was most common (49%, 13 studies with 501 events), while the pooled rate of thrombosis was 25% (16 studies with 309 events) and in-hospital mortality was 51% (17 studies, 693/1390 patients).
Conclusions
Despite advancements in ECMO, the optimal approach for anticoagulation monitoring remains undefined. Most studies in this review did not establish a significant relationship between ACT levels and haemostatic complications. Based on the current evidence, ACT does not appear to be a reliable tool for monitoring anticoagulation in patients receiving ECMO, and alternative methods should be considered.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Anaesthesiology and Intensive Care, Medical University of Innsbruck, Anichstraße. 35, 6020 Innsbruck, Austria.
- Anaesthesia and Intensive Care Department, Pain Therapy Service, Cagliari University, 09100 Cagliari, Italy.
- Institute of Medical Statistics and Informatics, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
- Surgical Oncology Clinic, Institute of Oncology and Radiology of Serbia, 11000 Belgrade, Serbia.
ORCID-Profile: Daniel Schwaiger, Lukas Schausberger, Benedikt Treml, Dragana Jadzic, Nicole Innerhofer, Christoph Oberleitner, Zoran Bukumirić, Sasa Rajsic
Zitieren
APA
Schwaiger, D., Schausberger, L., Treml, B., Jadzic, D., Innerhofer, N., Oberleitner, C., Bukumirić, Z., Spurnić, I., & Rajsic, S. (2025). Activated Clotting Time and Haemostatic Complications in Patients Receiving ECMO Support: A Systematic Review. Journal of Cardiovascular Development and Disease, 12(7), 267. https://doi.org/10.3390/jcdd12070267
Vancouver
Schwaiger D, Schausberger L, Treml B, Jadzic D, Innerhofer N, Oberleitner C, et al. Activated Clotting Time and Haemostatic Complications in Patients Receiving ECMO Support: A Systematic Review. Journal of Cardiovascular Development and Disease. 2025;12(7):267. doi:10.3390/jcdd12070267
BibTeX
@article{Schwaiger2025,
author = {Schwaiger, Daniel and Schausberger, Lukas and Treml, Benedikt and Jadzic, Dragana and Innerhofer, Nicole and Oberleitner, Christoph and Bukumirić, Zoran and Spurnić, Igor and Rajsic, Sasa},
title = {Activated Clotting Time and Haemostatic Complications in Patients Receiving ECMO Support: A Systematic Review},
journal = {Journal of Cardiovascular Development and Disease},
year = {2025},
volume = {12},
number = {7},
pages = {267},
doi = {10.3390/jcdd12070267}
}
EUVIMED